Our Market Position
TriloDocs' Unique Market Position
TriloDocs occupies a distinctive position as ”An AI Platform Built Specifically by Medical Writers.” Our dual AI approach: combining deterministic AI together with generative AI (Large Language Model - LLM), embodies the human-machine partnership philosophy described by Bloomberg (Matsuyama, 2023).
Guided by Dr. Barry Drees’ expertise as former EMWA President, TriloDocs represents the future of responsible AI implementation in medical writing: ”Making the work of the medical writer easier, faster and more accurate”.
Industry-wide AI Transformation
A 2024 PwC study projects that innovative pharmaceutical companies could see their operating margins climb from 20% today to over 40% by 2030 with strategic AI adoption. The study estimates that AI-driven improvements could contribute over $250 billion USD in additional value within the next five years.
Human-Machine Partnership Philosophy
Bloomberg Businessweek highlighted that “creating new drugs will continue to be a partnership between humans and machines” (Matsuyama, 2023). This collaborative approach recognizes that technology enhances rather than replaces human expertise in pharmaceutical development.
Technology Landscape: Dual AI Approaches
The industry employs two distinct methodologies: generative AI that can reduce document creation time by 50%, and deterministic rule-based systems that provide controlled, predictable results for complex data processing (Bleys et al., 2024; Huanbutta et al., 2024).
Medical Writing Market Opportunity
McKinsey & Co. estimated in 2024 that generative AI could generate $60 billion to $110 billion USD annually for pharmaceutical and medical-product industries by accelerating drug development and approval processes (Bleys et al., 2024). Major pharmaceutical companies including Takeda, Sanofi, and AstraZeneca are actively investing in AI partnerships (Matsuyama, 2023).
